Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Brain Behav Immun. 2012 Nov 29;31:143–152. doi: 10.1016/j.bbi.2012.11.011

Table 2.

Baseline measurements vs. Week 8 of sertraline treatment for MDD group.

Baseline Week 8 n Paired-t p
HDRS 18.71 ± 3.22 10.24 ± 6.32 17 5.23 <.001
F2-IsoP (ng/ml) 0.047 ± 0.016 0.048 ± 0.019 13 0.07 0.94
IL-6 (pg/ml) 0.96 ± 0.84 1.31 ± 0.98 17 −2.37 0.03
IL-10 (pg/ml) 0.27 ± 0.35 0.37 ± 0.62 17 −0.19 0.85
IL-6/IL-10 12.92 ± 14.52 16.06 ± 16.19 17 −1.62 0.13

Data are means ± SD of raw data. p values were calculated using paired-sample t-tests of log-transformed F2-IsoP and cytokine values. Certain sample sizes and baseline values for the MDD’s in this table differ from those in Table 1, because only MDD’s with both baseline and Week 8 data are included in Table 2.